Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Escalating Multiple Dose Study to Evaluate the Safety, Toxicity, Pharmacokinetics, and Preliminary Activity of BTX-1188 in Subjects With Advanced Malignancies

NCT05144334 is registered in ClinicalTrials.gov with Biotheryx, Inc. as lead sponsor.

NCT NCT05144334
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05144334 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Escalating Multiple Dose Study to Evaluate the Safety, Toxicity, Pharmacokinetics, and Preliminary Activity of BTX-1188 in Subjects With Advanced Malignancies
Lead sponsor
Biotheryx, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
January 24, 2022
Completion date
September 12, 2023
Enrollment
8 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, advanced solid tumor, non hodgkin lymphoma